US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Pfizer Inc.

PFENYSE

53.91

USD
-0.08
(-0.15%)
Market Closed
12.36P/E
1Forward P/E
0.48P/E to S&P500
302.484BMarket CAP
2.91%Div Yield
Upcoming Earnings
26 Jul-1 Aug
Shares Short
5/13/22
57.67M
Short % of Float
1.03%
Short % of Shares Outs.
1.03%
% Held by Insiders
0.04%
% Held by Institutions
69.18%
Beta
0.71
PEG Ratio
-9.94
52w. high/low
61.71/38.48
Avg. Daily Volume
27.49M
Return %
Stock
S&P 500
1 year
38.76
(3.64)
3 years
34.71
43.84
5 years
76.46
68.07
Scale: |
High
Low
26.31
21.10
23.00
13.53
18.02
11.02
19.32
13.28
20.78
15.78
24.75
19.69
30.83
24.03
31.42
26.10
34.59
27.01
35.47
26.80
35.44
29.32
44.09
31.50
42.28
32.23
43.08
26.45
61.71
33.36
58.55
45.40
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
6.68
7.00
7.18
7.14
8.44
8.63
7.93
7.57
7.82
7.91
8.68
8.80
9.14
9.29
7.54
14.51
16.46
Earnings per share
2.67
1.18
1.20
1.23
1.03
1.28
1.96
3.23
1.44
1.13
1.18
3.57
1.90
2.92
1.73
3.92
4.44
FCF per share
2.15
1.66
2.46
2.20
1.24
2.38
2.11
2.39
2.41
2.11
2.28
2.39
2.32
1.79
2.09
5.33
5.67
Dividends per share
0.96
1.15
1.27
0.79
0.76
0.80
0.88
0.97
1.04
1.12
1.20
1.28
1.36
1.44
1.52
1.56
1.57
CAPEX per share
0.28
0.27
0.25
0.17
0.19
0.21
0.18
0.22
0.25
0.24
0.33
0.37
0.37
0.47
0.50
0.48
0.50
Book Value per sh.
9.85
9.40
8.56
12.85
10.93
10.51
10.92
11.20
11.24
10.48
9.78
11.94
10.80
11.34
11.38
13.78
13.61
Comm.Shares outs.
7,242
6,917
6,727
7,007
8,036
7,817
7,442
6,813
6,346
6,176
6,089
5,970
5,872
5,569
5,555
5,601
5,610
Avg. annual P/E ratio
9.1
20.3
15.2
12.0
15.5
14.4
11.2
8.5
20.0
28.2
26.2
9.0
19.6
12.9
20.2
10.7
12.4
P/E to S&P500
0.5
1.2
0.7
0.2
0.7
0.9
0.8
0.5
1.1
1.4
1.2
0.4
0.8
0.5
0.5
0.4
0.5
Avg. annual div. yield
3.9%
4.8%
6.9%
5.3%
4.8%
4.3%
4.0%
3.5%
3.6%
3.5%
3.9%
4.0%
3.7%
3.8%
4.3%
3.7%
3.2%
Revenue (m)
48,371
48,418
48,296
50,009
67,809
67,425
58,986
51,584
49,605
48,851
52,824
52,546
53,647
51,750
41,908
81,288
92,367
Operating margin
29.5%
21.3%
31.1%
31.3%
20.9%
27.0%
30.5%
31.7%
27.2%
26.6%
26.0%
26.8%
28.0%
26.9%
20.9%
24.9%
27.4%
Depreciation (m)
5,293
5,200
5,090
4,757
8,487
9,026
7,611
6,410
5,537
5,157
5,757
6,269
6,384
6,010
4,777
5,191
5,152
Net profit (m)
19,337
8,144
8,104
8,635
8,257
10,009
14,570
22,003
9,135
6,960
7,215
21,308
11,153
16,273
9,616
21,979
24,966
Income tax rate
15.3%
11.0%
17.0%
20.3%
11.9%
31.5%
21.2%
27.4%
25.5%
22.2%
13.4%
(73.5)%
5.9%
7.8%
6.4%
7.6%
8.1%
Net profit margin
40.0%
16.8%
16.8%
17.3%
12.2%
14.8%
24.7%
42.7%
18.4%
14.2%
13.7%
40.6%
20.8%
31.4%
22.9%
27.0%
27.0%
Working capital (m)
25,560
25,014
16,067
24,445
31,859
29,659
32,796
32,878
36,071
14,405
7,834
10,714
18,068
(4,501)
9,147
17,022
15,152
Long-term debt (m)
5,546
7,314
7,963
43,193
38,410
34,931
31,036
30,462
31,541
28,818
31,398
32,666
32,429
35,955
35,571
34,757
34,416
Equity (m)
71,358
65,010
57,556
90,014
87,813
82,190
81,260
76,307
71,301
64,720
59,544
71,308
63,407
63,143
63,238
77,201
82,424
ROIC
19.3%
8.7%
9.6%
5.5%
5.9%
6.7%
9.4%
13.6%
6.9%
5.7%
5.9%
16.6%
9.7%
13.6%
8.4%
16.8%
18.1%
Return on capital
18.6%
8.0%
8.8%
5.7%
5.7%
8.4%
10.1%
16.1%
8.1%
6.1%
5.6%
7.9%
8.3%
11.5%
7.5%
13.9%
15.5%
Return on equity
27.1%
12.5%
14.1%
9.6%
9.4%
12.2%
17.9%
28.8%
12.8%
10.8%
12.1%
29.9%
17.6%
25.8%
15.2%
28.5%
30.3%
Plowback ratio
64.2%
2.1%
(5.4)%
35.7%
26.3%
37.7%
55.2%
70.1%
27.7%
0.3%
(1.4)%
64.1%
28.5%
50.6%
12.2%
60.3%
64.7%
Div.&Repurch./FCF
84.7%
152.6%
54.2%
36.1%
71.3%
82.0%
93.9%
140.3%
75.9%
100.6%
88.6%
88.8%
148.0%
169.2%
72.7%
29.2%
34.0%
Capital Structure
11 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 101,156
Total assets
$ 183,841
Long-term debt
$ 34,416
Cash and equiv.
$ 2,470
Goodwill
$ 50,211
Retained earnings
$ 111,193
Common stock
5,617
Enterprise Value
$ 334,430
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
9,830
12,221
31,069
Receivables
12,068
11,194
15,745
Inventory
8,283
8,046
9,059
Other
2,622
4,085
4,459
Current assets
32,803
35,067
59,693
Acc. Payable
4,220
4,309
5,578
Debt due
16,190
2,703
2,241
Other
16,894
18,908
34,852
Current liabilities
37,304
25,920
42,671
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
93.97%
18.38%
7.02%
Cash flow
157.23%
35.59%
14.92%
Earnings
128.57%
21.48%
28.18%
Dividends
3.42%
3.33%
3.29%
Book value
22.08%
2.68%
0.07%
Insider Trading
Type
Shares
Date
Damico Jennifer B.
Award
26
05/16/22
Damico Jennifer B.
Sale
4,000
05/16/22
Bourla Albert
Award
10
05/13/22
Johnson Rady A
Award
3
05/13/22
Sahni Payal
Sale
1,408
05/13/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
12,028
11,801
12,131
5,947
41,907
2021
14,582
18,977
24,094
23,635
81,288
2022
25,661
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.61
0.62
0.39
0.11
1.73
2021
0.87
0.99
1.45
0.61
3.92
2022
1.40
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.38
0.38
0.38
0.38
1.52
2021
0.39
0.39
0.39
0.39
1.56
2022
0.40
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Dr. Albert Bourla
Full-time employees:
79,000
City:
New York City
Address:
235 E 42ND ST
IPO:
Jan 17, 1944
Website:
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Recent News
· 24 May, 2022 · The Wall Street Journal
· 19 May, 2022 · The Wall Street Journal
· 17 May, 2022 · The Wall Street Journal
· 10 May, 2022 · The Wall Street Journal
· 3 May, 2022 · The Wall Street Journal
· 29 Apr, 2022 · The Wall Street Journal
· 7 Apr, 2022 · The Wall Street Journal
· 22 Mar, 2022 · The Wall Street Journal
· 14 Mar, 2022 · The Wall Street Journal
· 19 Feb, 2022 · The Wall Street Journal
· 18 Jan, 2022 · The Wall Street Journal
· 6 Jan, 2022 · The Wall Street Journal
· 3 Jan, 2022 · The Wall Street Journal
· 29 Dec, 2021 · The Wall Street Journal
· 22 Dec, 2021 · The Wall Street Journal
· 17 Dec, 2021 · The Wall Street Journal
· 14 Dec, 2021 · The Wall Street Journal